Oxford Biomedica plc, a gene and cell therapy group, has appointed Dr Frank Mathias as CEO. Dr Mathias will take up the role and a position on the board from March 2023. Since 2016 he has served as CEO of Rentschler Biopharma SE, tripling revenues and enhancing profitability at an even faster level. He led … Continue reading New CEO at listed Oxford Biomedica